2. Search Result
Search Result
Results for "

PDE2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

6

Natural
Products

6

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15455
    Roflumilast
    Maximum Cited Publications
    14 Publications Verification

    APTA-2217; BYK 20869; B9302-107

    		 Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDE4A4, PDE4B1, and PDE4B2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast
  • HY-103160A
    EHNA hydrochloride
    5 Publications Verification

    		 Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA hydrochloride is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA hydrochloride
  • HY-18252
    Avanafil
    1 Publications Verification

    TA1790

    		 Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil
  • HY-14992
    Bay 60-7550
    5+ Cited Publications

    BAY 607550

    		 Phosphodiesterase (PDE) Neurological Disease
    Bay 60-7550 is a potent and selective PDE2 inhibitor with a Ki of 3.8 nM.
    Bay 60-7550
  • HY-111371
    PF-05180999

    PF-999

    		 Phosphodiesterase (PDE) Neurological Disease
    PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC50 of 1.6 nM.
    PF-05180999
  • HY-14254A
    Olprinone
    1 Publications Verification

    Loprinone

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone
  • HY-10790
    Cilomilast
    3 Publications Verification

    SB-207499

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC50s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC50=74, 65, >100, and 83 μM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) .
    Cilomilast
  • HY-14254
    Olprinone Hydrochloride
    1 Publications Verification

    Loprinone Hydrochloride

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone Hydrochloride
  • HY-A0165
    Tofisopam

    		Phosphodiesterase (PDE) Neurological Disease
    Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent. Tofisopam can inhibit phosphodiesterase PDE isoenzyme activity, withIC50 values of 2.11 μM, 1.98 μM, 0.42 μM, and 0.92 μM for PDE-2A3, PDE-3A, PDE-4A1, and PDE-10A1, respectively. Tofisopam can be used for the study of anxiety .
    Tofisopam
  • HY-N1465
    Aristolochic acid D

    Aristolochic acid-IVa

    		 Phosphodiesterase (PDE) CDK Interleukin Related Inflammation/Immunology Cancer
    Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC50: 4.673 μM) and CDK2 (IC50: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .
    Aristolochic acid D
  • HY-112831
    Osoresnontrine
    1 Publications Verification

    BI-409306

    		 Phosphodiesterase (PDE) Neurological Disease
    Osoresnontrine (BI-409306) is a potent and selective PDE9A inhibitor, with an IC50 of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC50, 1.4 µM), PDE1C (IC50, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC50 all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders.
    Osoresnontrine
  • HY-102050
    PF-05085727

    		Phosphodiesterase (PDE) Neurological Disease
    PF-05085727 is a potent, selective and brain penetrant inhibitor of cGMP-dependent PDE2A (IC50=2 nM). PF-05085727 inhibits PDE2A >4,000-fold selectivity over PDE1 and PDE3-11 .
    PF-05085727
  • HY-U00186
    K134

    OPC33509

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC50s of K134 toward PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.
    K134
  • HY-103493
    TAK-915

    		Phosphodiesterase (PDE) Neurological Disease
    TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment .
    TAK-915
  • HY-179337
    PDE2-IN-1

    		Phosphodiesterase (PDE) PKA Neurological Disease
    PDE2-IN-1 is a potent and orally active PDE2 inhibitor with an IC50 of 0.6 μM, demonstrating neuroprotective effects. PDE2-IN-1 modulates the PKA/CREB/BDNF signaling pathway by inhibiting PDE2. PDE2-IN-1 improves memory deficits and cognitive impairment in an okadai acid (OKA)-induced Alzheimer’s disease (AD) mouse model. PDE2-IN-1 can be used for the research of AD .
    PDE2-IN-1
  • HY-15455S
    Roflumilast-d4
    1 Publications Verification

    APTA-2217-d4; BYK 20869-d4; B9302-107-d4

    		 Isotope-Labeled Compounds Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast-d4 is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .
    Roflumilast-d4
  • HY-111167
    AN-2898

    		Phosphodiesterase (PDE) Interleukin Related TNF Receptor IFNAR Inflammation/Immunology
    AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research .
    AN-2898
  • HY-132993
    Hcyb1

    		Phosphodiesterase (PDE) Neurological Disease
    Hcyb1 is a highly selective, orally active PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A (IC50=0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling .
    Hcyb1
  • HY-103160B
    EHNA

    		Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA
  • HY-103024
    ICI-63197

    		Environmental Pollutants Phosphodiesterase (PDE) Neurological Disease
    ICI-63197 is a phosphodiesterase 3 (PDE3) and PDE4 inhibitor with Ki values of 9 µM and 10 µM, respectively. ICI-63197 is selectivity against PDE1 and PDE2. ICI-63197 has antidepressant effects .
    ICI-63197
  • HY-102043
    PDM-631

    		Phosphodiesterase (PDE) Neurological Disease
    PDM-631 is a selective and orally active PDE2A inhibitor with blood-brain barrier penetration. PDM-631 exhibits potent inhibitory activity against human and rat recombinant PDE2A with IC50 values of 1.5 nM and 4.2 nM, respectively. PDM-631 increases cGMP levels in the rat cerebral cortex. PDM-631 can be used for the study of schizophrenia and neurodegenerative disorders .
    PDM-631
  • HY-156434
    PDE11A4-IN-1

    		Phosphodiesterase (PDE) Neurological Disease
    PDE11A4-IN-1 (compound 23b) is a potent and selective PDE11A4 inhibitor with an IC50 of 12 nM. PDE11A4-IN-1 show high selectivity for PDE11A4 over PDE1, PDE2, PDE7, PDE8, and PDE9 .
    PDE11A4-IN-1
  • HY-15455R
    Roflumilast (Standard)

    APTA-2217 (Standard); BYK 20869 (Standard); B9302-107 (Standard)

    		 Reference Standards Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast (Standard) is the analytical standard of Roflumilast. This product is intended for research and analytical applications. Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast (Standard)
  • HY-18252A
    Avanafil dibenzenesulfonate

    TA1790 dibenzenesulfonate

    		 Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil dibenzenesulfonate
  • HY-112631
    OPC 33540

    		Phosphodiesterase (PDE) Cardiovascular Disease
    OPC-33540 is a highly selective and competitive PDE3 inhibitor with IC50 values of 0.32 nM (PDE3A) and 1.5 nM (PDE3B). OPC-33540 exhibits IC50s against PDE1, PDE2, PDE4, PDE5, and PDE7 of 42.9, 52.3, 100.8, 2.5, and 51.3 μM, respectively. OPC-33540 significantly enhances cAMP accumulation in platelets and effectively inhibits thrombin-induced platelet aggregation. OPC-33540 can be used in antithrombotic studies .
    OPC 33540
  • HY-114023
    BML-288

    		Phosphodiesterase (PDE) Neurological Disease
    BML-288 (compound Oxindole 1) is a potent PDE2 inhibitor with an IC50 value of 40 nM. BML-288 has the potential for the research of osteoarthritis pain .
    BML-288
  • HY-142660
    PDE2A-IN-1

    		Phosphodiesterase (PDE) Neurological Disease
    PDE2A-IN-1 is a phosphodiesterase 2A (PDE2A) inhibitor with an IC50 value of 1.3 nM.
    PDE2A-IN-1
  • HY-15455S2
    Roflumilast-d3

    APTA-2217-d3; BYK 20869-d3; B9302-107-d3

    		 Isotope-Labeled Compounds Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast-d3 is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast-d3
  • HY-112704
    PDE5-IN-2

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-2 is a potent, highly selective, and orally active PDE5 inhibitor, with an IC50 of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC50s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .
    PDE5-IN-2
  • HY-15455S1
    Roflumilast-d4 N-Oxide

    		Phosphodiesterase (PDE) RSV Inflammation/Immunology
    Roflumilast-d4 N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .
    Roflumilast-d4 N-Oxide
  • HY-14254AR
    Olprinone (Standard)

    Loprinone (Standard)

    		 Phosphodiesterase (PDE) Reference Standards Cardiovascular Disease
    Olprinone (Standard) is the analytical standard of Olprinone. This product is intended for research and analytical applications. Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone (Standard)
  • HY-B0442S
    Vardenafil-d5

    		Isotope-Labeled Compounds Phosphodiesterase (PDE) Endogenous Metabolite Endocrinology
    Vardenafil-d5 is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .
    Vardenafil-d5
  • HY-105349
    T-0156

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .
    T-0156
  • HY-170435
    PDE5-IN-13

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .
    PDE5-IN-13
  • HY-N1465R
    Aristolochic acid D (Standard)

    Aristolochic acid-IVa (Standard)

    		 Reference Standards CDK Phosphodiesterase (PDE) Interleukin Related Inflammation/Immunology Cancer
    Aristolochic acid D (Standard) (Aristolochic acid-IVa (Standard)) is the analytical standard of Aristolochic acid D (HY-N1465). This product is intended for research and analytical applications. Aristolochic acid D (Aristolochic acid-IVa) is an orally active PDE2 (IC50: 4.673 μM) and CDK2 (IC50: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .
    Aristolochic acid D (Standard)
  • HY-164685
    T-0156 free base

    		Phosphodiesterase (PDE) Neurological Disease
    T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM). T-0156 free base inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway .
    T-0156 free base
  • HY-18252R
    Avanafil (Standard)

    TA1790 (Standard)

    		 Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite Cardiovascular Disease Endocrinology
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil (Standard)
  • HY-10790R
    Cilomilast (Standard)

    SB-207499 (Standard)

    		 Phosphodiesterase (PDE) Reference Standards Inflammation/Immunology
    Cilomilast (Standard) is the analytical standard of Cilomilast. This product is intended for research and analytical applications. Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC50s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC50=74, 65, >100, and 83 μM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) .
    Cilomilast (Standard)
  • HY-18252S3
    Avanafil-13C5

    TA1790-13C5

    		 Isotope-Labeled Compounds Endogenous Metabolite Phosphodiesterase (PDE) NO Synthase Cardiovascular Disease Endocrinology
    Avanafil- 13C5 (TA1790- 13C5) is 13C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil-13C5
  • HY-18252S1
    Avanafil-13C5,15N,d2

    		Endogenous Metabolite NO Synthase Phosphodiesterase (PDE) Isotope-Labeled Compounds Cardiovascular Disease Endocrinology
    Avanafil- 13C5, 15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .
    Avanafil-13C5,15N,d2
  • HY-103160AR
    EHNA hydrochloride (Standard)

    		Reference Standards Adenosine Deaminase Phosphodiesterase (PDE) Influenza Virus Infection Cardiovascular Disease Neurological Disease Cancer
    EHNA hydrochloride (Standard) is the analytical standard of EHNA hydrochloride (HY-103160A). This product is intended for research and analytical applications. EHNA hydrochloride is a potent and selective dual inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2)(IC50=4 μM) and adenosine deaminase (ADA). EHNA hydrochloride exerts a concentration inhibition of the cGMP-stimulated PDE II (cGs-PDE)(IC50:0.8 μM (human), 2 μM (porcine myocardium)), but has smaller inhibitory effect on the unstimulated PDE2 activity. EHNA hydrochloride play roles in mediating diverse pharmacological responses, including antiviral, antitumour and antiarrhythmic effects .
    EHNA hydrochloride (Standard)
  • HY-U00427
    PDE2A-IN-3

    		Phosphodiesterase (PDE) Neurological Disease Cancer
    PDE2A-IN-3 (Example Ic1) is a selective phosphodiesterase 2A (PDE2A) inhibitor with IC50s of 69 nM and 1762 nM for PDE2A and PDE10, respectively. PDE2A-IN-3 can be used for the study of neurological and psychiatric disorders .
    PDE2A-IN-3
  • HY-124173
    PF-06815189

    		Phosphodiesterase (PDE) Neurological Disease
    PF-06815189 is a phosphodiesterase 2A (PDE2A) inhibitor with an IC50 of 0.4 nM .
    PF-06815189
  • HY-180345
    ND-7001

    		Prostaglandin Receptor Neurological Disease
    ND-7001 is an inhibitor of PDE2 with an IC50 of 0.05 μM. ND-7001 exhibits good selectivity agianst PDE3 and PDE4. ND-7001 increases cGMP levels in primary neuronal cultures of rat cerebral cortical neurons. ND-7001 displays anxiolytic effects .
    ND-7001
  • HY-120195A
    PF-04827736

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PF-04827736 (compound (S)-3) is a selective PDE1 inhibitor with IC50 values of 9.1 nM, 38 nM and 42 nM for PDE1B, PDE1C and PDE1A. PF-04827736 selectively inhibits human PDE1 over the other 10 superfamily members (PDE2-PDE11). PF-04827736 can be used for the study of cardiovascular disease .
    PF-04827736
  • HY-120710
    DNS-8254

    		Phosphodiesterase (PDE) Neurological Disease
    DNS-8254 is an oral active and brain-penetrating PDE2a inhibitor with the IC50 of 8 nM. DNS-8254 shows memory enhancing effects in a rat model .
    DNS-8254
  • HY-A0165R
    Tofisopam (Standard)

    		Phosphodiesterase (PDE) Reference Standards Neurological Disease
    Tofisopam (Standard) is the analytical standard of Tofisopam (HY-A0165). This product is intended for research and analytical applications. Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent. Tofisopam can inhibit phosphodiesterase PDE isoenzyme activity, withIC50 values of 2.11 μM, 1.98 μM, 0.42 μM, and 0.92 μM for PDE-2A3, PDE-3A, PDE-4A1, and PDE-10A1, respectively. Tofisopam can be used for the study of anxiety .
    Tofisopam (Standard)
  • HY-103024R
    ICI-63197 (Standard)

    		Reference Standards Phosphodiesterase (PDE) Neurological Disease
    ICI-63197 (Standard) is the analytical standard of ICI-63197 (HY-103024). This product is intended for research and analytical applications. ICI-63197 is a phosphodiesterase 3 (PDE3) and PDE4 inhibitor with Ki values of 9 µM and 10 µM, respectively. ICI-63197 is selectivity against PDE1 and PDE2. ICI-63197 has antidepressant effects .
    ICI-63197 (Standard)
  • HY-14254R
    Olprinone Hydrochloride (Standard)

    Loprinone Hydrochloride (Standard)

    		 Phosphodiesterase (PDE) Reference Standards Cardiovascular Disease
    Olprinone (Hydrochloride) (Standard) is the analytical standard of Olprinone (Hydrochloride). This product is intended for research and analytical applications. Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .
    Olprinone Hydrochloride (Standard)
  • HY-168966
    JNJ-54082730

    		Phosphodiesterase (PDE) iGluR Neurological Disease
    JNJ-54082730 (Compound 1) is the orally active inhibitor for phosphodiesterase (PDE) that inhibits PDE2A, PDE3B, and PDE10A2 with IC50s of 0.95 nM, 6.17 μM (pIC50=5.21) and 87.1 nM (pIC50=7.06), respectively. JNJ-54082730 modulates the activity of AMPA receptor, enhance the synaptic plasticity and promotes the learning and memory function in rats models. JNJ-54082730 can cross blood-brain barrier .
    JNJ-54082730

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: